PillRx only · Tablet · Oral
Mercaptopurine
Mercaptopurine
3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US3 NDCs
3 active makers
3 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$0.982
Latest avg · Jul 22, 2026
-7%
Since Dec 17, 2025
3
Active US suppliers
80%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
11K
Rx · 2026 Q1
462K
Units dispensed
+15%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it3 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Hikma Pharmaceuticals USA Inc. | unknown | 2 | SUPPLYING |
| Florida Pharmaceutical Products, LLC | unknown | 2 | SUPPLYING |
| Golden State Medical Supply, Inc. | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Apr 4, 2014RECALLRecall (Class III): Mercaptopurine Tablets USP, 50 mg, 25 count bottle, Rx only, Roxanne Laboratories, Inc., Columbus, Ohio, 43216, NDC 005…
Labeling: Incorrect or Missing Lot and/or Exp Date: This recall is being conducted because the product was given 36 month expiration dates instead of the filed 24 months. — Recalling firm: Boehringer Ingelheim Roxane Inc — Nationwide